Jean-Marie Pagès

Dr. Jean-Marie Pagès

orcid

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2008 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
JPJean-Marie Pagès
Jean-Marie Pagès
CJChloë E. James
Chloë E. James
MWMathias Winterhalter
Mathias Winterhalter

1 March 2012 in FEMS Microbiology Reviews
Verified
Journal Article
Open access
PDF file
HNHiroshi Nikaido
Hiroshi Nikaido
JPJean-Marie Pagès
Jean-Marie Pagès
The broad-specificity efflux pump: an elegant and efficient mechanism which is involved in the first line of clinical resistance and contribute to the developme

18 September 2019 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
ADAnne Davin-Regli
Anne Davin-Regli
JLJean-Philippe Lavigne
Jean-Philippe Lavigne
JPJean-Marie Pagès
Jean-Marie Pagès
The genus Enterobacter is a member of the ESKAPE group, which contains the major resistant bacterial pathogens. First described in 1960, this group member has proven to be more complex as a result of the exponential evolution of phenotypic and genotypic methods. Today, 22 species belong to the Enterobacter genus. These species are described in the environment and have been reported as opportunistic pathogens in plants, animals, and humans.

2 December 2019 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
JVJulia Vergalli
Julia Vergalli
IBIgor Bodrenko
Igor Bodrenko
MMMuriel Masi
Muriel Masi
LMLucile Moynié
Lucile Moynié
SASilvia Acosta-Gutierrez
Silvia Acosta-Gutierrez
JPJean-Marie Pagès
Jean-Marie Pagès

1 May 2009 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
JPJean-Marie Pagès
Jean-Marie Pagès
LALeonard Amaral
Leonard Amaral

17 January 2007 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
AMAbdallah Mahamoud
Abdallah Mahamoud
JCJacqueline Chevalier
Jacqueline Chevalier
SASandrine Alibert-Franco
Sandrine Alibert-Franco
WKWinfried V. Kern
Winfried V. Kern
JPJean-Marie Pagès
Jean-Marie Pagès
After several decades of continuously successful antibiotic therapy against bacterial infections, we are now facing a worrying prospect: the accelerated evolution of antibiotic resistance to important human pathogens and the scarcity of new anti-infective drug families under development. Efflux is a general mechanism responsible for bacterial resistance to antibiotics. This active drug transport is involved in low intrinsic susceptibility, cross-resistance to chemically unrelated classes of molecules, and selection/acquisition of additional mechanisms of resistance. Thus, inhibition of bacterial efflux mechanisms appears to be a promising target in order to (i) increase the intracellular concentration of antibiotics that are expelled by efflux pumps, (ii) restore the drug susceptibility of resistant clinical strains, and (iii) reduce the capability for acquired additional resistance. Structurally unrelated classes of efflux pump inhibitors (EPIs) have been described and tested in the last decade, including some analogues of antibiotic substrates and new chemical molecules. Among the current collection of EPIs, only a few compounds have been studied taking into account the structure–activity relationships and the spectrum of activity in terms of antibiotics, pumps and bacteria. While large efforts have characterized an increasing number of bacterial efflux pumps and generated several potentially active EPIs, they have not elucidated the molecular basis of efflux transport and inhibition. Recent studies of pump–substrate complexes, the 3D resolution of the efflux pumps, the synthesis of novel compounds and molecular dynamic studies may generate new clues to decipher and select novel targets inside the efflux mechanisms and, finally, may result in a clinically useful molecule.